These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

759 related articles for article (PubMed ID: 30821155)

  • 1. Generation of CD19-Targeted Chimeric Antigen Receptor T Cells.
    Kiani J; Naderi M; Torabi-Rahvar M; Ranjbar A; Aghayan HR; Janzamin E; Ahmadbeigi N
    Arch Iran Med; 2019 Jan; 22(1):7-10. PubMed ID: 30821155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Building a CAR Garage: Preparing for the Delivery of Commercial CAR T Cell Products at Memorial Sloan Kettering Cancer Center.
    Perica K; Curran KJ; Brentjens RJ; Giralt SA
    Biol Blood Marrow Transplant; 2018 Jun; 24(6):1135-1141. PubMed ID: 29499327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial.
    Shah NN; Johnson BD; Schneider D; Zhu F; Szabo A; Keever-Taylor CA; Krueger W; Worden AA; Kadan MJ; Yim S; Cunningham A; Hamadani M; Fenske TS; Dropulić B; Orentas R; Hari P
    Nat Med; 2020 Oct; 26(10):1569-1575. PubMed ID: 33020647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimization of canine CD20 chimeric antigen receptor T cell manufacturing and in vitro cytotoxic activity against B-cell lymphoma.
    Sakai O; Igase M; Mizuno T
    Vet Comp Oncol; 2020 Dec; 18(4):739-752. PubMed ID: 32329214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Updates on CAR T-cell therapy in B-cell malignancies.
    Jacoby E; Shahani SA; Shah NN
    Immunol Rev; 2019 Jul; 290(1):39-59. PubMed ID: 31355492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells.
    Kueberuwa G; Zheng W; Kalaitsidou M; Gilham DE; Hawkins RE
    J Vis Exp; 2018 Oct; (140):. PubMed ID: 30394400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies.
    Ying Z; He T; Wang X; Zheng W; Lin N; Tu M; Xie Y; Ping L; Zhang C; Liu W; Deng L; Wu M; Feng F; Leng X; Du T; Qi F; Hu X; Ding Y; Lu XA; Song Y; Zhu J
    BMC Cancer; 2021 Feb; 21(1):198. PubMed ID: 33632155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.
    An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
    Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-Specific Reactive Oxygen Species Accelerators Improve Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies.
    Yoo HJ; Liu Y; Wang L; Schubert ML; Hoffmann JM; Wang S; Neuber B; Hückelhoven-Krauss A; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Mokhir A; Schmitt M; Sellner L
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31109083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors.
    Kochenderfer JN; Rosenberg SA
    Nat Rev Clin Oncol; 2013 May; 10(5):267-76. PubMed ID: 23546520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CAR T cells: driving the road from the laboratory to the clinic.
    Cheadle EJ; Gornall H; Baldan V; Hanson V; Hawkins RE; Gilham DE
    Immunol Rev; 2014 Jan; 257(1):91-106. PubMed ID: 24329792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis.
    Zhou H; Luo Y; Zhu S; Wang X; Zhao Y; Ou X; Zhang T; Ma X
    BMC Cancer; 2018 Sep; 18(1):929. PubMed ID: 30257649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation and degranulation of CAR-T cells using engineered antigen-presenting cell surfaces.
    Dirar Q; Russell T; Liu L; Ahn S; Dotti G; Aravamudhan S; Conforti L; Yun Y
    PLoS One; 2020; 15(9):e0238819. PubMed ID: 32976541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of anti-CD19 chimeric antigen receptor T cells for B-cell malignancies.
    Cao JX; Gao WJ; You J; Wu LH; Liu JL; Wang ZX
    Cytotherapy; 2019 Jul; 21(7):769-781. PubMed ID: 31160157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selecting the Optimal CAR-T for the Treatment of B-Cell Malignancies.
    Al-Juhaishi T; Ahmed S
    Curr Hematol Malig Rep; 2021 Feb; 16(1):32-39. PubMed ID: 33630232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. At the Bench: Chimeric antigen receptor (CAR) T cell therapy for the treatment of B cell malignancies.
    Daniyan AF; Brentjens RJ
    J Leukoc Biol; 2016 Dec; 100(6):1255-1264. PubMed ID: 27789538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric antigen receptor modified T cell therapy in B cell non-Hodgkin lymphomas.
    Levin A; Shah NN
    Am J Hematol; 2019 May; 94(S1):S18-S23. PubMed ID: 30652353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives.
    Mohty M; Gautier J; Malard F; Aljurf M; Bazarbachi A; Chabannon C; Kharfan-Dabaja MA; Savani BN; Huang H; Kenderian S; Nagler A; Perales MA
    Leukemia; 2019 Dec; 33(12):2767-2778. PubMed ID: 31690821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric Antigen Receptor T-Cell Therapies for Aggressive B-Cell Lymphomas: Current and Future State of the Art.
    Abramson JS; Lunning M; Palomba ML
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():446-453. PubMed ID: 31099671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeling anti-CD19 CAR T cell therapy in humanized mice with human immunity and autologous leukemia.
    Jin CH; Xia J; Rafiq S; Huang X; Hu Z; Zhou X; Brentjens RJ; Yang YG
    EBioMedicine; 2019 Jan; 39():173-181. PubMed ID: 30579863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.